KRAS and cancer: As an example, one recent review estimates that KRAS G12D is targetable in ~10% of all pancreatic cancer patients, and that across the most common cancer types in the USA (colorectal, renal, lung, endometrial and cervical) G12D mutant peptides presented in the context of HLA-A*03 could be targetable in ~1% of all patients, numerically equivalent to many specific small molecule inhibitor therapies [123].